Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.32 |
| ▸ | HRH1 | P35367 | 5/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493042 | 1.00 | BACE1 (0.34) | BACE1BACE2HRH3ADRA1AHRH1 | |
| SCHEMBL3494220 | 0.94 | BACE1 (0.36) | BACE1BACE2HRH3ADRA1AHRH1 | |
| SCHEMBL3494217 | 0.94 | BACE1 (0.36) | BACE1BACE2HRH3ADRA1AHRH1 | |
| SCHEMBL3493505 | 0.94 | BACE1 (0.38) | BACE1HRH3ADRA1AHRH1ADRA1B | |
| SCHEMBL3493571 | 0.90 | ADRA1A (0.35) | ADRA1AHRH1ADRA1BATM | |
| SCHEMBL3494731 | 0.89 | BACE1 (0.34) | BACE1HRH3ADRA1AHRH1ADRA1B | |
| SCHEMBL3492727 | 0.88 | BACE1 (0.42) | BACE1HRH3ADRA1AHRH1ATM | |
| SCHEMBL3492725 | 0.88 | BACE1 (0.42) | BACE1HRH3ADRA1AHRH1ATM | |
| SCHEMBL3493173 | 0.88 | ATM (0.34) | BACE1HRH3ADRA1AHRH1ADRA1B | |
| SCHEMBL3493175 | 0.88 | ATM (0.34) | BACE1HRH3ADRA1AHRH1ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | claimed |
| EP-2091328-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | claimed |
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2091328-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885HRH3 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.